Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 2
1975 1
1976 1
1979 1
1980 1
1981 1
1983 2
1986 2
1987 1
1989 2
1990 2
1991 5
1992 2
1993 4
1995 3
1996 2
1997 6
1998 4
1999 2
2000 9
2001 6
2002 8
2003 4
2004 16
2005 18
2006 16
2007 19
2008 23
2009 17
2010 16
2011 25
2012 22
2013 19
2014 26
2015 18
2016 22
2017 24
2018 25
2019 35
2020 55
2021 37
2022 36
2023 18
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

505 results

Results by year

Filters applied: . Clear all
Page 1
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group. Loriot Y, et al. N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323. N Engl J Med. 2019. PMID: 31340094 Clinical Trial.
We initially randomly assigned the patients to receive erdafitinib in either an intermittent or a continuous regimen in the dose-selection phase of the study. On the basis of an interim analysis, the starting dose was set at 8 mg per day in a continuous regimen (selecte …
We initially randomly assigned the patients to receive erdafitinib in either an intermittent or a continuous regimen in the dose-selectio …
Effect of low glycaemic index or load dietary patterns on glycaemic control and cardiometabolic risk factors in diabetes: systematic review and meta-analysis of randomised controlled trials.
Chiavaroli L, Lee D, Ahmed A, Cheung A, Khan TA, Blanco S, Mejia, Mirrahimi A, Jenkins DJA, Livesey G, Wolever TMS, Rahelić D, Kahleová H, Salas-Salvadó J, Kendall CWC, Sievenpiper JL. Chiavaroli L, et al. BMJ. 2021 Aug 4;374:n1651. doi: 10.1136/bmj.n1651. BMJ. 2021. PMID: 34348965 Free PMC article.
DATA SOURCES: Medline, Embase, and the Cochrane Library searched up to 13 May 2021. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Randomised controlled trials of three or more weeks investigating the effect of diets with low glycaemic index (GI)/glycaemic load (GL) in diabet …
DATA SOURCES: Medline, Embase, and the Cochrane Library searched up to 13 May 2021. ELIGIBILITY CRITERIA FOR SELECTING STUDIES: Rando …
Prediction of postoperative pulmonary complications in a population-based surgical cohort.
Canet J, Gallart L, Gomar C, Paluzie G, Vallès J, Castillo J, Sabaté S, Mazo V, Briones Z, Sanchis J; ARISCAT Group. Canet J, et al. Anesthesiology. 2010 Dec;113(6):1338-50. doi: 10.1097/ALN.0b013e3181fc6e0a. Anesthesiology. 2010. PMID: 21045639 Free article.
BACKGROUND: Current knowledge of the risk for postoperative pulmonary complications (PPCs) rests on studies that narrowly selected patients and procedures. Hypothesizing that PPC occurrence could be predicted from a reduced set of perioperative variables, we aimed to devel …
BACKGROUND: Current knowledge of the risk for postoperative pulmonary complications (PPCs) rests on studies that narrowly selected pa …
Probiotics for treating eczema.
Makrgeorgou A, Leonardi-Bee J, Bath-Hextall FJ, Murrell DF, Tang ML, Roberts A, Boyle RJ. Makrgeorgou A, et al. Cochrane Database Syst Rev. 2018 Nov 21;11(11):CD006135. doi: 10.1002/14651858.CD006135.pub3. Cochrane Database Syst Rev. 2018. PMID: 30480774 Free PMC article.
We formally assessed reporting bias by preparing funnel plots, and we performed trial sequential analysis for the first primary outcome - eczema symptoms at the end of active treatment.We used GRADE to assess the quality of the evidence for each outcome (in italic font). M …
We formally assessed reporting bias by preparing funnel plots, and we performed trial sequential analysis for the first primary outcome - ec …
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study.
Abida W, Campbell D, Patnaik A, Bryce AH, Shapiro J, Bambury RM, Zhang J, Burke JM, Castellano D, Font A, Ganju V, Hardy-Bessard AC, McDermott R, Sautois B, Spaeth D, Voog E, Piulats JM, Pintus E, Ryan CJ, Merseburger AS, Daugaard G, Heidenreich A, Fizazi K, Loehr A, Despain D, Simmons AD, Dowson M, Go J, Watkins SP, Chowdhury S. Abida W, et al. Eur Urol. 2023 Sep;84(3):321-330. doi: 10.1016/j.eururo.2023.05.021. Epub 2023 Jun 3. Eur Urol. 2023. PMID: 37277275 Clinical Trial.
CONCLUSIONS: The final TRITON2 results confirm the clinical benefit and manageable safety profile of rucaparib in patients with mCRPC, including those with an alteration in BRCA or select non-BRCA DDR gene. PATIENT SUMMARY: Almost half of TRITON2 patients with BRCA-mutated …
CONCLUSIONS: The final TRITON2 results confirm the clinical benefit and manageable safety profile of rucaparib in patients with mCRPC, inclu …
Functionally Separable Font-invariant and Font-sensitive Neural Populations in Occipitotemporal Cortex.
Zhou Z, Vilis T, Strother L. Zhou Z, et al. J Cogn Neurosci. 2019 Jul;31(7):1018-1029. doi: 10.1162/jocn_a_01408. Epub 2019 Apr 2. J Cogn Neurosci. 2019. PMID: 30938590
In contrast, bilateral shape-selective lateral occipital cortex and posterior fusiform showed considerable sensitivity to font changes during the viewing of repeated words. Although the visual word form area and the left middle occipital gyrus showed some evidence o …
In contrast, bilateral shape-selective lateral occipital cortex and posterior fusiform showed considerable sensitivity to font …
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO, Necchi A, Park SH, García-Donas J, Huddart RA, Burgess EF, Fleming MT, Rezazadeh Kalebasty A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Akapame S, Santiago-Walker AE, Monga M, O'Hagan A, Loriot Y; BLC2001 Study Group. Siefker-Radtke AO, et al. Lancet Oncol. 2022 Feb;23(2):248-258. doi: 10.1016/S1470-2045(21)00660-4. Epub 2022 Jan 11. Lancet Oncol. 2022. PMID: 35030333 Clinical Trial.
We aimed to assess the long-term efficacy and safety of the selected regimen of erdafitinib determined in the initial part of the study. ...The investigator-assessed objective response rate for patients treated with the selected erdafitinib regimen was 40 (40%; 95% …
We aimed to assess the long-term efficacy and safety of the selected regimen of erdafitinib determined in the initial part of the stu …
Stepwise application of ECG and electrogram-based criteria to ensure electrical resynchronization with left bundle branch pacing.
Pujol-López M, Ferró E, Borràs R, Garre P, Guasch E, Jiménez-Arjona R, Garcia-Ribas C, Doltra A, Niebla M, Carro E, Roca-Luque I, Guichard JB, Puente JL, Uribe L, Vázquez-Calvo S, Castel MÁ, Arbelo E, Porta-Sánchez A, Sitges M, Tolosana JM, Mont L. Pujol-López M, et al. Europace. 2023 Jun 2;25(6):euad128. doi: 10.1093/europace/euad128. Europace. 2023. PMID: 37294671 Free PMC article. Clinical Trial.
In the first step, presence of either right bundle branch conduction delay pattern (qR or rSR in V1) or left bundle branch capture Plus (QRS 120 ms) resulted in 95% sensitivity and 100% specificity to predict LBBP resynchronization, with an accuracy of 95.8%. In the second step, …
In the first step, presence of either right bundle branch conduction delay pattern (qR or rSR in V1) or left bundle branch capture Plus (QRS …
Non-Nucleoside Agonists of the Adenosine Receptors: An Overview.
Dal Ben D, Lambertucci C, Buccioni M, Martí Navia A, Marucci G, Spinaci A, Volpini R. Dal Ben D, et al. Pharmaceuticals (Basel). 2019 Oct 8;12(4):150. doi: 10.3390/ph12040150. Pharmaceuticals (Basel). 2019. PMID: 31597388 Free PMC article. Review.
Potent and selective adenosine receptor (AR) agonists are of pharmacological interest for the treatment of a wide range of diseases and conditions. Among these derivatives, nucleoside-based agonists represent the great majority of molecules developed and reported to date. …
Potent and selective adenosine receptor (AR) agonists are of pharmacological interest for the treatment of a wide range of diseases a …
Cytokines as therapeutic targets in primary Sjögren syndrome.
Retamozo S, Flores-Chavez A, Consuegra-Fernández M, Lozano F, Ramos-Casals M, Brito-Zerón P. Retamozo S, et al. Pharmacol Ther. 2018 Apr;184:81-97. doi: 10.1016/j.pharmthera.2017.10.019. Epub 2017 Oct 29. Pharmacol Ther. 2018. PMID: 29092775 Review.
The most recent etiopathogenic advances in SjS are shedding some light in the search for new highly-selective biological therapies without the adverse effects of the standard drugs currently used (corticosteroids and immunosuppressant drugs). ...
The most recent etiopathogenic advances in SjS are shedding some light in the search for new highly-selective biological therapies wi …
505 results